Drug Trial Radar · NCT00056407
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,231
Actual
Start
Mar 2003
Primary completion
Jan 2009
Study completion Apr 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 13, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Male only, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.
Conditions
- Neoplasms, Prostate
Interventions
DutasterideDrug
After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
PlaceboDrug
After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)
- Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)
- Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach)Time frame: Years 1-2, Years 3-4, and Overall (Years 1-4)
Locations
932 sites in 42 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Homewood, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Anchorage, Alaska
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Sun City, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Atherton, California
GSK Investigational Site
Culver City, California
GSK Investigational Site
Encino, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Irvine, California
GSK Investigational Site
La Mesa, California
GSK Investigational Site
Laguna Hills, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Mather, California
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Orange, California
GSK Investigational Site
Pico Rivera, California
GSK Investigational Site
Poway, California
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Salinas, California
GSK Investigational Site
San Bernardino, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
Showing 40 of 932 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.